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Abstract. Triple‑negative breast cancer (TNBC) has a
poorer prognosis compared with other sub-groups. In the
current study, survival associated with locoregional treatment of females with TNBC was investigated. Specifically,
468 patients with stage I‑III TNBC treated between 2002
and 2009 were identified. Data included patient and tumor
characteristics, treatment received and survival. Data
were compared using χ2 and Fisher's exact tests, as well
as MANOVA. Kaplan‑Meier curves were generated. The
study cohort had a mean age of 54±13 years old with a
mean follow‑up period of 51±21 months. Of 468 patients,
249 (53%) underwent lumpectomy, 63 (14%) underwent
simple mastectomy (SM) and 156 (33%) underwent modified
radical mastectomy (MRM). Overall, 263 (56%) received
adjuvant radiation, including 178/249 (71%) following
lumpectomy, 13/63 (21%) following SM and 72/156 (46%)
following MRM (P<0.0001). Following control for potential confounders in univariate tests, adjuvant radiation was
associated with improved overall survival in the total cohort
(HR, 0.46; 95% CI, 0.31‑0.68; P=0.0001). When comparing
survival by surgical type, receipt of adjuvant radiation significantly improved survival in the lumpectomy group (HR,
0.30; 95% CI, 0.16‑0.58; P=0.0004), but was not associated
with improved survival in the SM group (HR, 0.38; 95% CI,
0.05‑3.04; P=0.36) or in the MRM group (HR, 0.79; 95% CI,
0.46‑1.34; P= 0.38). The survival benefit of adjuvant radiation in these TNBC patients is attributed to those undergoing
breast‑conserving therapy. There was no benefit in either
mastectomy group. These data warrant validation from
prospective trials, in order to develop tailored locoregional
treatment for patients with TNBC.

Correspondence to: Dr Julie A. Margenthaler, Department of
Surgery, Washington University School of Medicine, Campus Box
8109, 660 S. Euclid Ave, St. Louis, MO 63110, USA
E‑mail: margenthalerj@wudosis.wustl.edu

Key words: triple‑negative breast cancer, radiation therapy, survival

Introduction
Triple‑negative breast cancer (TNBC) accounts for 15‑20% of
all breast cancers in the USA (1‑3). Treatment for TNBC [tumors
that are estrogen receptor (ER)‑negative, progesterone receptor
(PR)‑negative and human epidermal growth factor receptor 2
(HER2) non‑amplified] continues to be a challenge due to the
fact that it is, by definition, insensitive to the hormonal therapies
and trastuzumab that have been developed to treat other types
of breast cancer. These tumors appear to be exquisitely sensitive
to chemotherapy with reported complete pathological response
in 21‑31% of TNBC tumors in patients treated with neoadjuvant
chemotherapy (4,5). Despite this, these tumors are considered
aggressive and have shorter intervals for locoregional recurrence, distant metastasis and disease‑free survival (1,6‑8).
Gene expression profiling has resulted in the classification
of breast cancer into five molecular subtypes: Luminal A
(ER+, PR+ and Her2‑), luminal B (ER+, PR+ and Her2+),
basal‑like (ER‑, PR‑ and Her2‑; triple‑negative) Her2‑enriched
(ER‑/PR‑/Her2+) and the normal breast‑like subtype. Recent
studies have focused on whether molecular subtype is indicative of prognosis and response to treatment, but the data on
directed‑associated treatment is still in its infancy (6-8). As a
result, chemotherapy continues to be the mainstay of treatment
for TNBC breast cancers. However, recently, there has been
interest in determining whether radiation therapy provides any
additional benefit to patients with TNBC tumors, regardless of
initial surgical management.
There are currently no specialized guidelines for the treatment of TNBC. In general, radiation therapy is indicated for
all patients with invasive carcinoma of the breast under the
following conditions: i) received breast‑conserving therapy
(BCT); ii) underwent mastectomy with tumor >5 cm or with
positive margins; or iii) underwent mastectomy with positive
axillary nodes. Recently, however, there have been several
studies that have aimed to determine the outcomes of patients
with TNBC tumors who received radiation therapy, in comparison to those who did not. The results of these studies appear to
indicate that patients with TNBC tumors who received radiation therapy had decreased risk of locoregional recurrence and
increased overall survival in comparison to those that did not
receive radiation therapy (9,10). As a result, the present study
was performed in order to determine whether similar results
were observed in our study population.
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Μaterials and methods
Study design. Approval from the institutional review board
of Washington University School of Medicine (St. Louis,
MO, USA) was obtained prior to the initiation of this study.
It was determined that written consent from patients was
not required given the retrospective nature of the study. We
retrospectively identified 493 patients from our prospectively
maintained database with a diagnosis of stage I‑III TNBC
who were treated between January 1, 2002 and December
31, 2009. Of these, 25 patients were diagnosed with stage IV
breast cancer at the time of diagnosis and subsequently
excluded from the analysis. As a result, 468 patients were
included in the total study population. Patients were determined to have a TNBC based on immunohistochemical
methods. A designation of receptor negative status was
conducted based on having <1% stained cells. Fluorescence
in situ hybridization was used to confirm HER‑2/neu status
if immunohistochemistry detected 2+ staining. Patients
were subsequently divided based on whether they underwent lumpectomy or BCT versus simple mastectomy (SM)
versus modified radical mastectomy (MRM). Data collected
included patient and tumor characteristics; surgical, systemic
and radiation treatment received; and breast cancer‑specific
survival.
Statistical analysis. The primary outcome was overall survival
(OS), which was defined as time from the date of treatment
initiation to the date of mortality due to any cause. Survivors
were censored at the date of last contact. The distributions of
patient and clinical characteristics (including age, ethnicity,
nodal status, tumor grade and size, receipt of chemotherapy and
type of surgery) by the status of radiotherapy were compared
using χ2 or Fisher's exact tests, as appropriate. Survival curves
by radiotherapy status were estimated using the Kaplan‑Meier
product‑limit method and compared by the log‑rank test.
Univariate Cox proportional hazard models were fit to identify
factors significantly associated with OS. For those factors with
P<0.15 in the univariate analyses, a multivariate Cox model
was constructed using a backward selection procedure to
assess whether the receipt of radiotherapy was an independent
predictor of survival. Two‑way interaction terms between
radiotherapy and other factors in the multivariate Cox model
were also assessed. All analyses were two‑sided and P<0.05
was considered to indicate a statistically significant difference.
Statistical analyses were performed using SAS (SAS Institute,
Cary, NC, USA).
Results
During the study period, between January 2002 and
December 2009, 468 patients with stage I‑III TNBC were
identified. Of 468 patients, 249 (53%) underwent lumpectomy,
63 (14%) underwent simple mastectomy and 156 (33%) underwent modified radical mastectomy. The mean age of the study
population was 54±13 years old with a mean follow‑up period
of 51±21 months. The patient and tumor characteristics of the
study population are described in Table Ι.
Overall, 263 (56%) received adjuvant radiation therapy,
including 178/249 (71%) following lumpectomy, 13/63 (21%)
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Table I. Patient and tumor characteristics of 468 patients with
triple‑negative breast cancer treated between 2002 and 2009.
Characteristic
Age, years
<50
≥50
Ethnicity
Caucasian
African American
Other
Clinical T stage
T1
T2
T3
T4
Unknown
Histology
Invasive ductal
Invasive lobular
Mixed/other
Nuclear grade
1
2
3
Unknown
Node status
N0
N1
N2
N3
Unknown
Stage
1
2a
2b
3
Unknown

n (%)
193 (41.2)
275 (58.8)
287 (61.3)
172 (36.8)
9 (1.9)
166 (35.5)
176 (37.6)
37 (7.9)
30 (6.4)
59 (12.6)
386 (82.5)
9 (1.9)
73 (15.6)
6 (1.3)
55 (11.8)
391 (83.6)
16 (3.4)
295 (63.0)
100 (21.4)
12 (2.6)
16 (3.4)
45 (9.6)
149 (31.8)
142 (30.3)
54 (11.5)
66 (14.1)
57 (12.2)

following SM and 72/156 (46%) following MRM (P<0.0001),
as listed in Table ΙΙ. Of the 263 patients that received adjuvant radiation therapy, information regarding their treatment
regimen was only available for 152 patients (57.8%). For these
patients, the mean initial radiation dose was 5,137±938 cGy
with a range of 2,000‑10,240 cGy and median of 5,000 cGy.
Of these patients, 84 (55.3%) went on to receive an additional
boost of radiation with a mean of 1,292±629 cGy, median of
1,000 cGy and range of 1,000‑6,400 cGy. Factors predictive of
receipt of adjuvant radiation included type of surgical therapy
received (lumpectomy vs. SM and MRM), increasing tumor
size and positive nodal status (P<0.05 for each). The groups
did not differ with regard to age, ethnicity, tumor size or
nuclear grade (Table III).
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Table II. Locoregional treatment of 468 patients with triple‑negative breast cancer.
Type of surgery

Received radiation, n (%)

No radiation, n (%)

178 (71.5)
13 (20.6)
72 (46.2)

71 (28.5)
50 (79.4)
84 (53.8)

Breast‑conserving therapy
Simple mastectomy
Modified radical mastectomy

A

B

C

D

Figure 1. Kaplan‑Meier survival curves for 468 patients with triple‑negative breast cancer according to receipt of adjuvant radiation therapy versus no radiation
therapy (RT). (A) Entire cohort of 468 patients. (B) Patients who underwent lumpectomy (n=249). (C) Patients who underwent simple mastectomy (n=63).
(D) Patients who underwent modified radical mastectomy (MRM) (n=156).

In the total cohort, univariate analysis demonstrated
that TNBC patients who underwent radiation therapy had
significantly improved overall survival (HR, 0.462; 95% CI,
0.311‑0.69; P=0.0001) compared with those who did not
receive adjuvant radiation therapy. The overall four‑year
survival for patients who received adjuvant radiation therapy
was 77.34 versus 59.8% in patients who did not receive adjuvant radiation therapy. Smaller tumor size (T1/T2), negative
nodal status, receipt of systemic chemotherapy and receipt of
adjuvant radiation therapy were all significantly associated
with improved overall survival (P<0.05 for each). However,
when comparing survival by surgical type, receipt of adjuvant radiation therapy significantly improved survival in the
lumpectomy group (HR, 0.30; 95% CI, 0.16‑0.58; P=0.001),

but was not significantly associated with improved survival
in the SM group (HR, 0.38; 95% CI, 0.05‑3.04; P=0.34) or in
the MRM group (HR, 0.77; 95% CI, 0.46‑1.34; P=0.38). Fig. 1
illustrates the survival curves for all TNBC study patients,
as well as the survival curves for patients treated by surgical
intervention. Overall four‑year survival for patients treated by
surgical intervention was 78.9, 81.78 and 54.26% for lumpectomy, SM and MRM groups, respectively.
Discussion
The majority of studies have shown that TNBC is a particularly aggressive form of breast cancer. These tumors tend
to present in younger patients, at a larger size (>2 cm),
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Table III. Correlation between patient and tumor characteristics and receipt of radiation therapy in 468 patients with triple‑negative breast cancer.
Characteristic
Age, years
<50
≥50
Ethnicity
Caucasian
African American
Other
Clinical T stage
T1
T2
T3
T4
Unknown
Nuclear grade
1
2
3
Unknown
Node status
N0
N1
N2
N3
Unknown
Chemotherapy
Adjuvant
Neoadjuvant
Unknown

Radiation, n (%)

No radiation, n (%)

P‑value

83 (40.5)
122 (59.5)

110 (41.8)
153 (58.2)

NS

125 (61.0)
77 (37.6)
3 (1.5)

162 (61.6)
95 (36.1)
6 (2.3)

NS

72 (35.1)
75 (36.6)
14 (6.8)
11 (5.4)
33 (16.1)

94 (35.7)
101 (38.4)
23 (8.8)
19 (7.2)
26 (9.9)

NS

2 (1.0)
22 (10.7)
170 (82.9)
11 (5.4)

4 (1.5)
33 (12.6)
291 (84.0)
5 (1.9)

NS

141 (68.8)
37 (18.1)
0 (0)
7 (3.4)
20 (9.8)

154 (58.6)
63 (24.0)
12 (4.6)
9 (3.4)
25 (9.5)

0.0047

106 (51.7)
45 (22.0)
54 (26.3)

128 (48.7)
106 (40.3)
22 (11.0)

<0.0001

with positive lymph nodes and with a higher mitotic index
and grade (3,8). Patients with TNBC demonstrate poorer
overall breast cancer‑specific survival and shorter time to
recurrence, including locoregional recurrence and distant
metastasis (3,8,11,12). In addition, studies have also documented that the incidence of locoregional recurrence in
TNBC patients peaks during years 1‑4, but then sharply
declines (8). Another study demonstrated that individuals
with TNBC were more likely to have locoregional failure,
in comparison to distant metastasis (11). As a result, the
impetus for identifying the optimal locoregional treatment
strategy for TNBC is of paramount importance. Yet, the
connection between locoregional control and survival has yet
to be elucidated for this sub‑group of patients.
Currently, there are no specific guidelines for the management of TNBC. Systemic chemotherapy continues to be the
mainstay of treatment, as the majority of TNBCs tend to be
exquisitely sensitive to chemotherapy. However, how this
systemic therapy specifically impacts locoregional control
remains less clear. Radiation therapy is indicated for the
majority of patients who undergo BCT and is also indicated

for a sub‑set of patients following mastectomy if high‑risk
features for locoregional recurrence exist, for example
multiple positive lymph nodes, tumors >5 cm, presence of
lymphovascular invasion or positive surgical margins. There
are no tumor subtype‑specific guidelines regarding adjuvant
radiation therapy. Given that adjuvant radiation therapy is used
for local control and TNBCs appear to have a higher incidence
of locoregional recurrence, there has been recent interest in
determining whether TNBC, a specific subtype of breast
cancer, is likely to benefit from radiation therapy regardless of
surgical intervention. Therefore, several retrospective studies
have analyzed the role of radiation therapy in TNBC, but their
findings are conflicting (11-14).
Dragun et al found that there was no difference in progression‑free and locoregional‑free survival in TNBC patients with
or without radiation therapy during years 1‑3. However, the
radiation group had a higher probability of locoregional‑free
survival after three years (13). Abdulkarim et al found that
T1‑2N0 TNBC patients treated with MRM without RT had
a significantly increased risk of locoregional recurrence in
comparison with those treated with BCT, but there was no
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difference in overall survival (9). Wang et al completed a
randomized trial comparing adjuvant chemotherapy versus
adjuvant chemotherapy and radiation in stage I and II TNBCs
who underwent modified radical mastectomy. The authors
found improved recurrence‑free and overall survival in patients
who received combined therapy in comparison to those who
only received chemotherapy (10). While the data appears to
be inconsistent with respect to whether radiation decreases
locoregional recurrence, there is even less clear evidence of
the effect of radiation therapy on survival.
The current study has several limitations. Firstly, this
is a retrospective study and, therefore, patients were not
randomized to receipt of radiation therapy. There are specific
guidelines regarding indications for adjuvant radiation
therapy, but it is clear that adherence to these guidelines
may not always occur and the reasons for this are unclear
retrospectively. For example, it is noteworthy that of the
249 patients who underwent BCT, 71 patients (28.5%) did not
receive any radiation therapy. It would be interesting to know
if there were clinicopathological versus social factors that
affected why these patients did not receive radiation. Another
weakness of the study is the lack of consistency amongst the
treatment regimens, including the radiation therapy regimen
and whether or not patients received chemotherapy. The
median radiation dose was 5,000 cGy and ~50% of those
patients received an additional median boost of 1,000 cGy.
These are fairly standard regimens, but the regimens did
vary, reflecting the heterogeneity of patients that receive
some or all of their care at our single institution. In future
prospective studies, a more standardized radiation therapy
must be outlined.
Although the retrospective nature of this study is a
potential limitation, we propose that it represents one of the
largest analyses of the impact of adjuvant radiation therapy
in patients with TNBC, with the primary goal of determining
the impact of radiation therapy on overall survival, rather than
on locoregional recurrence. The study indicates that, while
overall survival of patients with TNBC improved with radiation therapy, this improvement was attributed to those patients
who underwent BCT. There was no difference in the overall
survival of patients who underwent either form of mastectomy
according to receipt of radiation therapy. These observations
corroborate those documented by Kyndi et al in their study
of high‑risk patients who underwent MRM (14). The authors
also found no survival benefit for post‑mastectomy radiation in
patients with TNBC.
Radiation therapy is not innocuous, nor is it without cost.
Determining whether certain sub‑groups of patients with
TNBC may be able to forego adjuvant radiation therapy is of
significant clinical interest.
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